Articles tagged with: Pomalidomide


[ by | May 23, 2013 1:44 pm | 6 Comments ]
Manhattan Tales: Spring Awakening

One of the advantages of living in the U.S. north­east is the chance to ex­peri­ence the change of the seasons. This year, the arrival of spring coin­cided with a new medical regimen for me and what has seemed like a rebirth of my own life.

As I described in my April column, this past win­ter was the season of my dis­content. In less than three months, I experienced two bouts of pneu­monia. I was at the hospital at least once a week, and I had near constant gastric distress. …

Read the full story »


[ by | May 20, 2013 2:42 pm | 3 Comments ]
Latest Myeloma Research To Be Presented At The American Society Of Clinical Oncology Annual Meeting (ASCO 2013)

The American Society of Clinical Oncology will hold its 49th annual meeting May 31 through June 4 in Chicago.

Similar to previous years, more than 25,000 clinical specialists from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care. The theme for this year’s meeting is “Building Bridges to Conquer Cancer.”

During the meeting, there will be presentations and seminars about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists more than 

Read the full story »


[ by | Apr 12, 2013 2:16 pm | 2 Comments ]
Update Presented About Cereblon And Resistance To Pomalyst, Revlimid, And Thalidomide In Myeloma Patients (IMW 2013)

During a session at the International Myeloma Workshop (IMW) held in Japan last week, Dr. Keith Stewart from the Mayo Clinic summarized the latest findings from research related to the protein cereblon and its im­pact on certain myeloma treatments.

Dr. Stewart reported that low levels of cereblon are associated with lower re­sponse rates and reduced survival outcomes in multiple myeloma patients treated with the immunomodulatory agents Revlimid (lena­lido­mide), thalidomide (Thalomid), and Pomalyst (pomalidomide).

He explained that, with further investigation, these findings may eventually help physicians …

Read the full story »


[ by | Apr 10, 2013 5:44 pm | One Comment ]
Pomalyst Plus Low-Dose Dexamethasone Is Active In High-Risk Relapsed Myeloma Patients (IMW 2013)

A sub-analysis of recent Phase 2 clinical trial results indicates that Pomalyst in combination with low-dose dexamethasone is effective and safe in multiple myeloma patients with high-risk chromosomal ab­nor­malities who did not re­spond to prior therapy.

The findings were presented by Dr. Paul Richardson of the Dana-Farber Cancer Institute in Boston at the International Myeloma Workshop (IMW) in Kyoto, Japan, this past Sunday.

In the new analysis, high-risk patients were defined as those with a deletion in chromosome 17 (del17p) or the translocation t(4;14).

Although the response rates were lower and survival …

Read the full story »


[ by | Mar 22, 2013 2:52 pm | 4 Comments ]
The Top Myeloma Research Of 2012

Looking back at all that has happened in the world of multiple myeloma since January of 2012, it is hard not to be impressed by the many im­por­tant devel­op­ments that took place.

There is the obvious fact that, during that time, not one, but two new drugs to treat myeloma were approved by the U.S. Food and Drug Adminis­tra­tion (FDA).  Prior to 2012, the FDA had not approved a novel anti-myeloma therapy in over six years.

Yet 2012 was meaningful to the myeloma community for reasons beyond the activity at …

Read the full story »